CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRL Health Care · Health Care Equipment & ServicesEach grade is a single reported quarter's assessment, never an average — a card shows the grade at the newest quarter in view, so it follows the period and range controls above. Latest scored quarter: 2026-06-27.
▼−33 over range · as of 2026-06-27
Revenue -2.7% YoY, earnings -102.8% YoY · sector avg 66
▼−32 over range · as of 2026-06-27
-0.1% net margin, -8% return on equity, 9% free-cash-flow margin, profitable in 4 of last 8 quarters · sector avg 45
▼−20 over range · as of 2026-06-27
Net debt 6.3x EBITDA, 4x interest coverage, 1.3x current ratio · sector avg 68
Trailing twelve months · ending 2026-06-27 · green = improving · click a row to chart it
Revenue $4.0B −0.7% Gross margin — — Operating margin 2.3% +0.5pp Net margin -6.0% −1.4pp Net income -$238.5M — CHARTEDFilings
TTM 23-09 → TTM 26-06 · following the period bar 15 match| Year | Q1 | Q2 | Q3 | FY |
|---|---|---|---|---|
| 2026 | 10-Q Q1 2026 | 10-Q Q2 2026 | no filing | no filing |
| 2025 | 10-Q Q1 2025 | 10-Q Q2 2025 | 10-Q Q3 2025 | 10-K FY 2025 |
| 2024 | 10-Q Q1 2024 | 10-Q Q2 2024 | 10-Q Q3 2024 | 10-K FY 2024 |
| 2023 | 10-Q Q1 2023 | 10-Q Q2 2023 | 10-Q Q3 2023 | 10-K FY 2023 |
| 2022 | no filing | no filing | no filing | 10-K FY 2022 |
All 15 filings
10-K FY 2024 2025-02-19 Pro → 10-Q Q3 2024 2024-11-06 Pro → 10-Q Q2 2024 2024-08-07 Pro → 10-Q Q1 2024 2024-05-09 Pro → 10-K FY 2023 2024-02-14 Pro → 10-Q Q3 2023 2023-11-08 Pro → 10-Q Q2 2023 2023-08-09 Pro → 10-Q Q1 2023 2023-05-11 Pro → 10-K FY 2022 2023-02-22 Pro →Filing-level fact detail is a Pro feature. The grades and figures above are free. See Pro plans
Trends
| Period | Period end | Revenue |
|---|---|---|
| TTM 23-09 | 2023-09-30 | $4.2B |
| TTM 23-12 | 2023-12-30 | $4.1B |
| TTM 24-03 | 2024-03-30 | $4.1B |
| TTM 24-06 | 2024-06-29 | $4.1B |
| TTM 24-09 | 2024-09-28 | $4.1B |
| TTM 24-12 | 2024-12-28 | $4.0B |
| TTM 25-03 | 2025-03-29 | $4.0B |
| TTM 25-06 | 2025-06-28 | $4.0B |
| TTM 25-09 | 2025-09-27 | $4.0B |
| TTM 25-12 | 2025-12-27 | $4.0B |
| TTM 26-03 | 2026-03-28 | $4.0B |
| TTM 26-06 | 2026-06-27 | $4.0B |
| Period | Period end | Net income |
|---|---|---|
| TTM 23-09 | 2023-09-30 | $474.9M |
| TTM 23-12 | 2023-12-30 | $474.6M |
| TTM 24-03 | 2024-03-30 | $444.5M |
| TTM 24-06 | 2024-06-29 | $441.5M |
| TTM 24-09 | 2024-09-28 | $423.8M |
| TTM 24-12 | 2024-12-28 | $22.2M |
| TTM 25-03 | 2025-03-29 | -$25.3M |
| TTM 25-06 | 2025-06-28 | -$67.0M |
| TTM 25-09 | 2025-09-27 | -$82.3M |
| TTM 25-12 | 2025-12-27 | -$144.3M |
| TTM 26-03 | 2026-03-28 | -$184.7M |
| TTM 26-06 | 2026-06-27 | -$238.5M |
| Period | Period end | Operating income |
|---|---|---|
| TTM 23-09 | 2023-09-30 | $648.1M |
| TTM 23-12 | 2023-12-30 | $617.3M |
| TTM 24-03 | 2024-03-30 | $575.3M |
| TTM 24-06 | 2024-06-29 | $562.1M |
| TTM 24-09 | 2024-09-28 | $528.0M |
| TTM 24-12 | 2024-12-28 | $227.3M |
| TTM 25-03 | 2025-03-29 | $176.0M |
| TTM 25-06 | 2025-06-28 | $124.5M |
| TTM 25-09 | 2025-09-27 | $140.9M |
| TTM 25-12 | 2025-12-27 | $25.2M |
| TTM 26-03 | 2026-03-28 | $70.4M |
| TTM 26-06 | 2026-06-27 | $90.1M |
Grade history
Point-in-time: each period shows the grade of the quarter it ends at — grades are never summed or averaged across a window.
Hover to read every grade at a period · shared with the trends chart · axis fixed 0–100
| Period | Period end | Growth | Quality | Safety |
|---|---|---|---|---|
| TTM 23-09 | 2023-09-30 | 38 | 43 | 41 |
| TTM 23-12 | 2023-12-30 | 29 | 50 | 41 |
| TTM 24-03 | 2024-03-30 | 17 | 42 | 42 |
| TTM 24-06 | 2024-06-29 | 22 | 47 | 41 |
| TTM 24-09 | 2024-09-28 | 16 | 47 | 42 |
| TTM 24-12 | 2024-12-28 | 6 | 19 | 25 |
| TTM 25-03 | 2025-03-29 | 8 | 23 | 21 |
| TTM 25-06 | 2025-06-28 | 10 | 23 | 21 |
| TTM 25-09 | 2025-09-27 | 14 | 19 | 24 |
| TTM 25-12 | 2025-12-27 | 11 | 13 | 14 |
| TTM 26-03 | 2026-03-28 | 7 | 10 | 21 |
| TTM 26-06 | 2026-06-27 | 5 | 11 | 21 |